explore -WSS

explore

author：leisure time 2025-10-01 00:49:08 - browse：4

The state’s celebrated cluster of biotechs has hatched breakthrough medicines for everything from COVID and cystic fibrosis to multiple rare diseases. It has pioneered cutting-edge research in exotic fields like messenger RNA, gene editing, and gene therapies.

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Instead, the field, which has scientific roots in Massachusetts, is dominated by a pair of global pharma giants: Denmark’s Novo Nordisk, maker of the blockbuster drugs Wegovy and Ozempic, and Indianapolis-based Eli Lilly, which produces the fast-selling Mounjaro.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： FDA approves RSV monoclonal antibody for infants, toddlers

WSS

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

AI can’t replace a physician’s gut feeling

All of Us, NIH's precision medicine initiative, gets a big boost

Sanders adds drug shortage policies to pandemic preparedness bill

Explaining an after

Wikipedia

explore

hotspot

Medical leaders decry Supreme Court decision on affirmative action

STAT Readout: The latest on Wegovy, Mounjaro, and Covid shots

Psychedelics group wrestles with new pharma identity

Humans aren't the only ones with an imagination. Rats have it too

United colonoscopy coverage change 'may cost lives,' doctors say

How to convince healthy people to buy insurance

Activists slam private health insurers over coverage restrictions

Listen: Wegovy in the brain & pivotal Alzheimer's data

BioMarin wins approval for gene therapy to treat hemophilia A

Coloradans with cystic fibrosis could lose access to Trikafta

hotspot

AI can’t replace a physician’s gut feeling

How to convince healthy people to buy insurance

Sanofi seeks simpler, safer CRISPR sickle cell cure

Sarepta Duchenne therapy fails to meet primary endpoint in trial

Readout LOUD podcast: The Sarepta saga, decoding biotech hype

Key Senate panel to consider PBM, drug pricing reform package

hotspot

entertainment

hotspot

leisure time